Haemonetics Stock Analysis

Haemonetics Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 19.46. The company has Price/Earnings To Growth (PEG) ratio of 1.21. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people. To learn more about Haemonetics call Ronald Gelbman at 781 848 7100 or check out https://www.haemonetics.com.

Haemonetics Investment Alerts

Haemonetics Largest EPS Surprises

View All Earnings Estimates

Haemonetics Environmental, Social, and Governance (ESG) Scores

Haemonetics Thematic Classifications

Haemonetics Stock Institutional Investors

Note, although Haemonetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Haemonetics Market Capitalization

The company currently falls under 'Mid-Cap' category with a total capitalization of 2.87 B.

Haemonetics Profitablity

The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.21 %, which entails that for every 100 dollars of revenue, it generated $0.21 of operating income.

Management Efficiency

Haemonetics has Return on Asset of 0.0645 % which means that on every $100 spent on assets, it made $0.0645 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.193 %, implying that it generated $0.193 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 1.1 B, whereas Other Current Assets are forecasted to decline to about 52.6 M.

Technical Drivers

As of the 25th of February, Haemonetics retains the Risk Adjusted Performance of (0.09), standard deviation of 2.13, and Market Risk Adjusted Performance of (1.42). Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics standard deviation, maximum drawdown, kurtosis, as well as the relationship between the information ratio and potential upside to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 61.68 per share. Given that Haemonetics has information ratio of (0.17), we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.

Haemonetics Price Movement Analysis

Haemonetics Insider Trading Activities

Haemonetics Outstanding Bonds

Haemonetics Predictive Daily Indicators

Haemonetics Corporate Filings

Haemonetics Forecast Models

Haemonetics' time-series forecasting models are one of many Haemonetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Haemonetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Haemonetics Bond Ratings

Haemonetics financial ratings play a critical role in determining how much Haemonetics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Haemonetics' borrowing costs.

Haemonetics Debt to Cash Allocation

Haemonetics has 1.22 B in debt with debt to equity (D/E) ratio of 1.12, which is OK given its current industry classification. Haemonetics has a current ratio of 2.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Haemonetics to invest in growth at high rates of return.

Haemonetics Common Stock Shares Outstanding Over Time

Haemonetics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Haemonetics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Haemonetics Debt Ratio

39.0

It looks as if about 61% of Haemonetics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Haemonetics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Haemonetics, which in turn will lower the firm's financial flexibility.

Haemonetics Corporate Bonds Issued

Haemonetics Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Haemonetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Haemonetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Haemonetics. By using and applying Haemonetics Stock analysis, traders can create a robust methodology for identifying Haemonetics entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Haemonetics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Haemonetics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Haemonetics stock analysis indicators help investors evaluate how Haemonetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Haemonetics shares will generate the highest return on investment. By understating and applying Haemonetics stock analysis, traders can identify Haemonetics position entry and exit signals to maximize returns.

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.